alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2006143EN.01002501.xml

| 17.6.2006 | EN | Official Journal of the European Union | C 143/25 |
| --- | --- | --- | --- |

17.6.2006

EN

Official Journal of the European Union

C 143/25

---

Reference for a preliminary ruling by the Tribunale di Napoli lodged on 30 March 2006 — Giuseppina Montoro and Michelangelo Liguori v Beth Israel Deaconess Medical Center

(Case C-170/06)

(2006/C 143/45)

Language of the case: Italian

Referring court

Tribunale di Napoli

Parties to the main proceedings

Applicants: Giuseppina Montoro and Michelangelo Liguori

Applicants:

Defendant: Beth Israel Deaconess Medical Center

Defendant:

Question referred

Interpretation of Article 5(3) of the Brussels Convention of 1968 requested in order to establish whether or not, leaving aside the hypothesis of multiple instances of damage, the test of the courts for the place where the harmful event occurred can serve to found jurisdiction also for the courts of the place where the person injured became aware of the existence of damage attributable to an act that took place in another State.

---
**Exhibit 10.25**DESCRIPTION OF DIRECTORS AND NAMED EXECUTIVE OFFICERS COMPENSATIONThe compensation payable to all of the Company’s non-employee directors is as follows: **•** An annual cash retainer of $5,000.00.  **•** In addition, non-employee directors each receive $700.00 for each regular meeting of theBoard of Directors attended. **•** In addition, members of the Audit Committee are paid $250.00 for each Audit Committeemeeting attended and the Audit Committee Chairman is paid an annual retainer of $4,000.00.The compensation of executive officers is reviewed and adjusted on an annual basis as of theindividual’s anniversary date of hire, based upon the approval of the Executive CompensationCommittee of the Board of Directors.As of March 10, 2008, current annual salaries of each of the following executive officers is shownbelow:     Name SalaryDonita R. Koval $321,360 Daniel L. Warfel $240,900 David S. Runk $174,552 
34
#### Nelse MINOR v. STATE of Mississippi.

No. 48111.

Supreme Court of Mississippi.

Oct. 28, 1974.

Robert L. Netterville, Natchez, for appellant.

A. F. Summer, Atty. Gen. by Karen Gil-foy, Sp. Asst. Atty. Gen., Jackson, for ap-pellee.

PATTERSON, Justice:

Nelse Minor was indicted for murder and tried in the Circuit Court of Adams County. He was convicted of manslaughter and sentenced to ten years in the state penitentiary. He argues for reversal that the trial court erred in giving an instruction on murder and one on manslaughter since this required a compromise verdict of manslaughter when the facts would permit no verdict other than acquittal by way of accident or a conviction of murder.

Clarence McMorris was killed by a pistol shot in close proximity to his heart. At the time he was engaged in an altercation with appellant’s brother, Tet Minor. The appellant intervened by striking McMorris separating him from his brother and immediately thereafter his pistol fired, mortally wounding McMorris.

The jury was presented with conflicting evidence concerning the actual shooting. Willie King, Jr., testifying for the prosecution, stated that he heard the shot, turned and saw the weapon in the appellant’s hand and that his arm was extended. When questioned whether appellant was pointing it he answered: “Well, it was coming down when I saw it.” *“Q.*He was bringing it back?” “A. Yes, sir.”

The appellant presented a witness who heard him say “Oh Lord, it’s an accident” *249immediately after the shot was fired. Lawrence Minor, another brother of the appellant, contradicted King’s testimony, stating that McMorris had taken the pistol from the appellant and that during an ensuing struggle for the recovery of the weapon, it discharged killing McMorris. This witness stated the pistol was in Mc-Morris’ hand at the time it was fired.

The jury was thus presented an issue arising from conflicting testimony. It considered the evidence and resolved the conflict against the appellant. The jury being the sole judge of the weight and credibility of witnesses, we cannot say its verdict was in error. Marr v. State, 248 Miss. 281, 159 So.2d 167 (1963).

We conclude there was no error in granting the murder and manslaughter instructions. A defendant convicted of manslaughter may not complain at the giving of a murder instruction. *See*Bragg v. State, 210 So.2d 652 (Miss.1968), and the cases therein cited.

Moreover, the appellant not only voiced no objection to the manslaughter instruction at the time it was given, but obtained an instruction advising the jury not to compromise its verdict. The last instruction complemented others obtained by the defendant portraying his defense that McMorris’ death occurred by accident or misfortune. Overall, the instructions obtained by the parties properly informed the jury of the law of the case.

The record before us discloses sufficient evidence to support the verdict and there being no prejudicial error revealed by defense counsel or apparent from our study, we conclude that the judgment should be affirmed.

Affirmed.

RODGERS, P. J., and INZER, SMITH and BROOM, JJ., concur.
HomeSouth Korea

# South Korea

499 items

        -    Media Note  		Sixth United States-Republic of Korea Working Group Meeting on Democratic People’s Republic of Korea Cyber Threats	  March 28, 2024 
        -    Media Note  		Launching the U.S.-ROK Enhanced Disruption Task Force	  March 26, 2024 
        -    Special Briefing  		Digital Press Briefing with Uzra Zeya, Under Secretary of State for Civilian Security, Democracy, and Human Rights	  Uzra ZeyaMarch 20, 2024Asia Pacific Media Hub 
        -    Press Statement  		Secretary Blinken’s Travel to Vienna, Seoul, Manila, Jeddah, Cairo, and Tel Aviv	  Matthew MillerMarch 20, 2024 
        -    Depositary Actions - Treaty Affairs  		Trade and Investment – IPEF Supply Chain Agreement – Notification of Deposit of Instrument; Republic of Korea, March 18, 2024	   
        -    Department Press Briefing  		Department Press Briefing – March 18, 2024	  Vedant PatelMarch 18, 2024 
        -    Media Note  		Joint Statement on Efforts to Counter the Proliferation and Misuse of Commercial Spyware	  March 18, 2024 
        -    Remarks  		Secretary Antony J. Blinken At the Ministerial Conference of the Third Summit for Democracy	  Antony J. BlinkenMarch 17, 2024Shilla HotelSeoul, Republic of Korea 
        -    Remarks  		Secretary Antony J. Blinken At the Opening Ceremony of the Third Summit for Democracy	  Antony J. BlinkenMarch 17, 2024Shilla HotelSeoul, Republic of Korea 
        -    Notice to the Press  		Secretary Blinken to Deliver Remarks at the Third Summit for Democracy  	  March 16, 2024 

123…50next page

Back to Top
Exhibit 31.1

CERTIFICATION



I, C. Jayson Brentlinger, certify that:

1.

I have reviewed this Report on Form 10-QSB of Circuit Research Labs, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(c)

Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5.

The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):



---

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.

Date:  June 6, 2005.

/s/ C. Jayson Brentlinger

C. Jayson Brentlinger

Chief Executive Officer
HomeResources – Office of Language Services...Information for Freelance Linguists

# 									Information for Freelance Linguists							

Freelance contractors play a vital role in our office’s mission of providing foreign language interpreting and translating services to U.S. government officials and in support of U.S. foreign exchange and assistance programs. Please see the Interpreting and Translation sections for information about our selection process. To apply as a potential interpreter or translator, please complete an LS Testing Application Form [484 KB].

Contract interpreters and translators must be able to work legally in the United States but are not required to hold U.S. citizenship. Eligibility to work with the Office of Language Services will be determined by U.S. Citizen and Immigration Services guidelines and will be corroborated by verifying that all relevant documentation is presented with the application. If you have any doubts, please refer questions about general eligibility to your local USCIS office before applying. Because freelance contractors are not employees of the State Department, the Office of Language Services cannot sponsor visa applicants.

Contract interpreters and translators must undergo a background check to obtain a Moderate or High Public Trust certification if their applications are successful.

Permanent direct-hire interpreter and translator positions are very rare. When available, openings for staff positions will be published on www.usajobs.gov.

### Interpreting Information for Freelance Linguists

### Translating Information for Freelance Linguists

Back to Top
AD Economic Evaluation

Docket No. FAA-2013-0351 Directorate ID: 2009-SW-049-AD

Helicopter Model: Eurocopter France Model AS350B, BA, B1, B2, B3, and D; and AS355E, F, 

F1, F2, and N Helicopters

Number of Helicopters (U.S. Operators): 654 Helicopters in the US Registry.

Reason: The actions of this AD are intended to prevent loss of a tail rotor blade tab, which could 

result in excessive vibration and loss of control of the helicopter.

Costs:

Parts per Helicopter $100 for rivets

$100 for tab

Labor per Helicopter

(1 work-hour x $85/workhour for the inspection & 

riveting)

(4 work-hours x $85/workhour for the replacement)

$85

$340

Other (Explain)

Total Cost per Helicopter $185 for the inspection & riveting

$440 for the tab replacement

Total US Fleet Cost $120,990 for the inspection & riveting

Executive Order 12866:

Could the AD be considered a “significant regulatory action?” Yes ( ) No ()

DOT Regulatory Policies and Procedures:

Is the AD significant? Yes ( ) Explain Below No ()

Regulatory Flexibility Act:

Will the AD have a significant economic impact on a substantial number of small entities?

Yes ( ) No ()

Project Engineer: Gary Roach
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsExperimental Visualization of Flows in Packed Beds of SpheresThe flow experiment consisted of an oil tunnel, 76 x 76 mm in cross-section, packed with lucite spheres. The index of refraction of the working fluid and the spheres were matched such that the physical spheres invisible to the eye and camera. By seeding the oil and illuminating the packed bed with planar laser light sheet, aligned in the direction of the bulk flow, the system fluid dynamics becomes visible and the 2-D projection was recorded at right angles to the bulk flow. The planar light sheet was traversed from one side of the tunnel to the other providing a simulated 3-D image of the entire flow field. The boundary interface between the working fluid and the sphere rendered the sphere black permitting visualization of the exact locations of the circular interfaces in both the axial and transverse directions with direct visualization of the complex interstitial spaces between the spheres within the bed. Flows were observed near the surfaces of a plane and set of spheres as well as minor circles that appear with great circles and not always uniformly ordered. In addition to visualizing a very complex flow field, it was observed that flow channeling in the direction of the bulk flow occurs between sets of adjacent spheres. Still photographs and video recordings illustrating the flow phenomena will be presented.Document ID19970010765Acquisition SourceLegacy CDMSDocument TypeConference PaperAuthorsHendricks, R. C.*(NASA Lewis Research Center Cleveland, OH United States)*Lattime, S.*(B and C Engineering Associates, Inc. Akron, OH United States)*Braun, M. J.*(Akron Univ. Akron, OH United States)*Athavale, M. M.*(CFD Research Corp. Huntsville, AL United States)*Date AcquiredSeptember 6, 2013Publication DateJanuary 1, 1997Subject CategoryAircraft Propulsion And PowerReport/Patent NumberE-10527NASA-TM-107365NAS 1.15:107365Meeting InformationMeeting: Pacific Symposium on Flow Visualization and Image ProcessingLocation: Honolulu, HICountry: United StatesStart Date: February 23, 1997End Date: February 26, 1997Sponsors:Hawaii Univ.Accession Number97N15916Funding Number(s)PROJECT: RTOP 233-1B-1BDistribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19970010765.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
104TH CONGRESS

2D SESSION H. R. 3056

AN ACT

To permit a county-operated health insuring orgacounty. enrolls Medicaid beneficiaries residing in another program notwithstanding that the organization health insuring organizations under the Medicaid from certain requirements otherwise applicable to nization to qualify as an organization exempt
104TH CONGRESS

2D SESSION H. R. 3056

AN ACT

To permit a county-operated health insuring organization

to qualify as an organization exempt from certain requirements otherwise applicable to health insuring organizations under the Medicaid program notwithstanding

that the organization enrolls Medicaid beneficiaries residing in another county.
2

•HR 3056 EH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. PERMITTING COUNTY-OPERATED HEALTH IN4 SURING ORGANIZATIONS TO ENROLL MEDIC5 AID BENEFICIARIES RESIDING IN ANOTHER

6 COUNTY UNDER MEDICAID WAIVER FOR CER7 TAIN COUNTY-OPERATED HEALTH INSURING

8 ORGANIZATIONS.

9 (a) IN GENERAL.—Section 9517(c)(3)(B)(ii) of the

10 Consolidated Omnibus Budget Reconciliation Act of 1985

11 (42 U.S.C. 1396b note), as added by section 4734 of the

12 Omnibus Budget Reconciliation Act of 1990, is amended

13 by inserting ‘‘or counties’’ after ‘‘county’’.

14 (b) EFFECTIVE DATE.—The amendment made by

15 subsection (a) shall apply to quarters beginning on or

16 after October 1, 1996.

Passed the House of Representatives September 10,

1996.

Attest:

Clerk.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 By Notice dated April 17, 2009, and published in the 
                    **Federal Register**
                     on April 29, 2009, (74 FR 19598), Siemens Healthcare Diagnostics Inc., 
                    *Attn:*
                     RA, 100 GBC Drive, Mail Stop 514, Newark, Delaware 19702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug
ScheduleTetrahydrocannabinols (7370)
IEcgonine (9180)
IIMorphine (9300)
II
 The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator/controls which are DEA exempt products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siemens Healthcare Diagnostics Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Siemens Healthcare Diagnostics Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. E9-21531 Filed 9-4-09; 8:45 am] BILLING CODE 4410-09-P
H. R. 3056

One Hundred Fourth Congress

of the

United States of America

AT THE SECOND SESSION

Begun and held at the City of Washington on Wednesday,

the third day of January, one thousand nine hundred and ninety-six

An Act

To permit a county-operated health insuring organization to qualify as an organization exempt from certain requirements otherwise applicable to health insuring

organizations under the Medicaid program notwithstanding that the organization

enrolls Medicaid beneficiaries residing in another county.

Be it enacted by the Senate and House of Representatives of

the United States of America in Congress assembled,

SECTION 1. PERMITTING COUNTY-OPERATED HEALTH INSURING

ORGANIZATIONS TO ENROLL MEDICAID BENEFICIARIES

RESIDING IN ANOTHER COUNTY UNDER MEDICAID

WAIVER FOR CERTAIN COUNTY-OPERATED HEALTH

INSURING ORGANIZATIONS.

(a) IN GENERAL.—Section 9517(c)(3)(B)(ii) of the Consolidated

Omnibus Budget Reconciliation Act of 1985 (42 U.S.C. 1396b note),

as added by section 4734 of the Omnibus Budget Reconciliation

Act of 1990, is amended by inserting ‘‘or counties’’ after ‘‘county’’.

(b) EFFECTIVE DATE.—The amendment made by subsection (a)

shall apply to quarters beginning on or after October 1, 1996.

Speaker of the House of Representatives.

Vice President of the United States and

President of the Senate.
# Countries & Areas

		Subscribe		

198 items

        -    		Bosnia and Herzegovina	  April 23, 2019 
        -    		Botswana	  August 2, 2019 
        -    		Brazil	  May 13, 2019 
        -    		Brunei	  April 19, 2019 
        -    		Bulgaria	  April 23, 2019 
        -    		Burkina Faso	  April 19, 2019 
        -    		Burma	  April 19, 2019 
        -    		Burundi	  April 19, 2019 
        -    		Cabo Verde	  April 19, 2019 
        -    		Cambodia	  April 19, 2019 

previous page12345…20next page

Back to Top
Exhibit 32.2

CERTIFICATION PURSUANT TO18 U.S.C. §1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Enzon Pharmaceuticals, Inc. (the Company) for the period ended March 31, 2009 as filed with the Securities and Exchange Commission on the
date hereof (the Report), I, Craig A. Tooman, Executive Vice President, Finance, and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to
my knowledge:

| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                               
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------
|
| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|

|            |  |                                      
|----------- |  | -------------------------------------
|May 7, 2009 |  | /s/ Craig A. Tooman                  
|            |  | Craig A. Tooman                      
|            |  | Executive Vice President, Finance and
|            |  | Chief Financial Officer              
|            |  | (Principal Financial Officer)        

---
**Exhibit 31.4****CERTIFICATION**I, Daniel L. Warfel, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 10-K of OmegaFinancial Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to theperiod covered by this report.        Date: 04/04/2008 /s/ Daniel L. Warfel   Daniel L. Warfel    Chief Financial Officer   
30
EXHIBIT 32.1

STATEMENT PURSUANT TO SECTION 906 THE SARBANES-OXLEY ACT OF 2002
BY PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER


      I, Keith Brackpool, herby certify, to my
knowledge, that:

      1. the accompanying Annual Report on Form 10-Q of
Cadiz Inc. for the period ended June 30, 2006 (the
"Report") fully complies with the requirements of Section
13(a) or 15(d), as applicable, of the Securities and
Exchange Act of 1934, as amended; and

      2. the information contained in the Report fairly
presents, in all material respects, the financial condition
and results of operations of Cadiz Inc.

      IN WITNESS WHEREOF, the undersigned has executed this
Statement as of the date first written above.

Dated: August 9, 2006


                              /s/ Keith Brackpool
                              ----------------------------------
                              Keith Brackpool
                              Chairman, Chief Executive Officer